Imperagen raises £5 million to use quantum physics, AI on enzyme engineering
AI-summarised brief · reviewed before publication
Imperagen, a biotech company, has raised £5 million in a seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone. The company, founded in 2021 by Manchester Institute of Biotechnology scientists, aims to improve enzyme engineering using quantum physics and AI. Imperagen's technology uses quantum physics-based simulation, AI models, and robots to explore millions of mutations and generate experimental data. The company hopes to make enzyme development faster, more reliable, and commercially accessible, with applications in pharmaceuticals, food, biofuels, and agriculture. Imperagen has raised £8.5 million to date and plans to hire AI specialists and expand its lab capabilities.
💡 Why It Matters
- · Faster enzyme engineering can accelerate drug discovery and make industrial production more sustainable.
- · Imperagen's technology has the potential to unlock more efficient and reliable bio-based product development.